scholarly journals High pretreatment serum CA19-9 level predicts a poor prognosis for patients with stage III colon cancer after curative resection and adjuvant chemotherapy

2019 ◽  
Vol 10 (16) ◽  
pp. 3810-3818 ◽  
Author(s):  
Wenhao Zhou ◽  
Fan Yang ◽  
Jianhong Peng ◽  
Fulong Wang ◽  
Yuzhu Lin ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Poor Prognosis ◽  
Curative Resection ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Pretreatment Serum

Prognostic impact of preoperative albumin to globulin ratio in curative colon cancer patients.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 647-647
Author(s):  
Yuji Toiyama ◽  
Hiroyuki Fujikawa ◽  
Yasuhiro Inoue ◽  
Hiroki Imaoka ◽  
Masato Okigami ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Early Recurrence ◽  
Stage I ◽  
Stage Iii ◽  
Prognostic Impact ◽  
Stage Iii Colon Cancer ◽  
Albumin To Globulin Ratio

647 Background: Albumin to globulin ratio (AGR) has been reported to predict long term mortality in patients with several cancers. However, prognostic impact of preoperative AGR in colon cancer patients with curative intent has not yet been fully addressed. Therefore, we, for the first time, investigated the association between AGR and clinico-pathological findings including overall survival (OS) and disease free survival (DFS) in stage I-III colon cancer patients. Methods: Clinicopathological findings including preoperative laboratory data (carcinoembryonic antigen [CEA] and AGR) from 251 curative colon cancer patients were assessed as indicators of early recurrence and poor prognosis in this retrospective study. AGR was calculated as [AGR = albumin/ (total protein - albumin)]. The cut-off value of AGR was 1.32 in current study. Results: Several clinicopathological categories related with tumor progression such as lymph node metastasis, T4 tumor, large tumor size, undifferentiated tumor, venous and lymphatic invasion, and high CEA were significantly associated with low AGR level. The patients with low AGR were significantly poorer OS (P = 0.001) and DFS (P = 0.003) than those with high AGR, respectively. In addition, multivariate analyses demonstrated that low AGR was independently associated with early recurrence (HR = 2.87, P = 0.007) and poor prognosis (HR = 2.56, P = 0.008), respectively. On the other hand, sub analysis of survival curves revealed that stage III colon cancer patients with low AGR were significantly poorer OS (P = 0.007) and DFS (P = 0.02) than those with high AGR, respectively. Furthermore, significantly poorer OS and DFS were also shown in stage I-II colon cancer patients with low AGR, respectively (OS: P = 0.02, DFS: P = 0.01). Conclusions: Preoperative AGR was an independent predictor of early recurrence and poor prognosis in curative colon cancer patients. AGR may represent a simple, potentially useful predictive biomarker for selecting stage I-II colon cancer patients who might need adjuvant chemotherapy. Furthermore, AGR may select candidates who are better to introduce more intensive adjuvant chemotherapy after curative operation in stage III colon cancer patients.

scholarly journals A Phase II Clinical Study of mFOLFOX6 /XELOX as Adjuvant Chemotherapy after Curative Resection of Stage III Colon Cancer: The FACOS Study

2016 ◽  
Vol 24 (1) ◽  
pp. 17-22 ◽  
Author(s):  
Keiichiro Ishibashi ◽  
Kensuke Kumamoto ◽  
Keiji Koda ◽  
Hiroyuki Kato ◽  
Genichi Nishimura ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Clinical Study ◽  
Adjuvant Chemotherapy ◽  
Phase Ii ◽  
Curative Resection ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
Phase Ii Clinical Study

scholarly journals The Latest Update of Prognostic Factors of Stage III Colon Cancer Who Underwent Curative Operation and Postoperative Adjuvant Chemotherapy

2019 ◽  
Vol 104 (9-10) ◽  
pp. 446-452
Author(s):  
Keigo Yokoi ◽  
Masanori Naito ◽  
Keishi Yamashita ◽  
Satoru Ishii ◽  
Toshimichi Tanaka ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Prognostic Factors ◽  
Adjuvant Chemotherapy ◽  
Poor Prognosis ◽  
Univariate Analysis ◽  
Stage Iii ◽  
Depth Of Invasion ◽  
Postoperative Adjuvant Chemotherapy ◽  
Free Survival ◽  
Stage Iii Colon Cancer

This study aimed to explore the predicting factor of the poor prognosis of stage III colon cancer. Adjuvant chemotherapy for stage III colon cancer has become popular. However, the choice of the optimal adjuvant chemotherapy regimen still remains unclear. A total of 135 patients with stage III colon cancer, treated with postoperative adjuvant chemotherapy from January 2007 to December 2012 at the Kitasato University East Hospital, were reviewed retrospectively in terms of clinicopathologic characteristics associated with survival and recurrence (median observation: 61 months). We used a multivariate Cox hazards model to identify independent prognostic factors in stage III colon cancer. Of the 135 patients, 38 had recurrence. Five-year overall survival was 83.9%, while 3-year recurrence-free survival was 72.8%. Oxaliplatin-containing adjuvant chemotherapy was almost exclusively applied to stage IIIB colon cancer. Univariate analysis of the negative prognostic factors were N2 (P = 0.0004); operation time (P = 0.0346); tumor size (P = 0.0092); depth of invasion (P = 0.005); histology (P = 0.0403); infiltration type (P < 0.0001); lymphatic permeation (ly3, P = 0.0001); and vascular permeation (v3, P = 0.0005). On multivariate analysis, the independent prognostic factors for relapse-free survival were v3 (P = 0.032) and N2 (P = 0.0216). Combination of the prognostic factors clearly stratified prognosis of stage III colon cancer patients, and those with either factor positive had a poor prognosis despite administration of adjuvant chemotherapy. Both v3 and pN2 may be critical prognostic factors in stage III colon cancer with adjuvant chemotherapy. This information would elucidate areas of concern in the present therapeutic strategy in stage III colon cancer.

Preplanned initial safety analysis of ACTS-CC 02 trial: A large randomized phase III trial of SOX versus UFT/LV as adjuvant chemotherapy for high-risk stage III colon cancer.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 572-572 ◽  
Author(s):  
Hiroya Takiuchi ◽  
Naohiro Tomita ◽  
Narikazu Boku ◽  
Toshiaki Watanabe ◽  
Kenjiro Kotake ◽  
...  
Keyword(s):  
Colon Cancer ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Adverse Events ◽  
Curative Resection ◽  
Phase Iii ◽  
Stage Iii ◽  
Postoperative Adjuvant Chemotherapy ◽  
Stage Iii Colon Cancer ◽  
To Receive

572 Background: The ACTS-CC 02 trial is designed to verify the superiority of postoperative adjuvant chemotherapy of S-1/Oxaliplatin (SOX) for patients with anyT, N2 colon cancer compared with UFT/Leucovorin (UFT/LV), which is one of standard adjuvant chemotherapies in Japan. To date, there have been no reported phase III trials evaluating SOX as postoperative adjuvant chemotherapy. This report presents initial safety data obtained from 50 patients who received SOX in the trial. Methods: Patients who underwent curative resection for anyT, N2 colon cancer were randomly assigned to receive either SOX (100 mg/m2 of oxaliplatin on day1, and 80 to 120 mg/day according to body surface area (BSA) of S-1 on days 1-14, every 21 days, 8 courses) or UFT/LV (300 to 600 mg/day according to BSA of UFT and 75 mg/day of LV on days 1-28, every 35 days, 5 courses). Data were collected from initial consecutive 50 patients assigned to the SOX group and analyzed when they were considered evaluable for safety as planned in the protocol. This ongoing trial is designed to accrue 1200 patients. As of September 15, 2011, 319 patients have been accrued. Results: Of 50 patients assigned to receive SOX, 48 were evaluable for safety. The median number of treatment courses was 5 (range: 1-8). The relative dose intensity of S-1 was 83.8% and that of oxaliplatin was 86.6%. Grade 3 adverse events were neutropenia (14.6%), thrombocytopenia (2.1%), ALT elevation (2.1%), diarrhea (8.3%), fatigue (2.1%), and peripheral sensory neuropathy (2.1%). Grade 4 adverse effects were not observed. Conclusions: In this initial safety analysis, the incidence and severity of adverse events with SOX were acceptable in patients with high risk stage III colon cancer after curative resection. Enrollment of patients is ongoing.

scholarly journals Estimating the optimal rate of adjuvant chemotherapy utilization for stage III colon cancer

2019 ◽  
Vol 8 (12) ◽  
pp. 5590-5599
Author(s):  
Safiya Karim ◽  
Christopher M. Booth ◽  
Kelly Brennan ◽  
Yingwei Peng ◽  
D. Robert Siemens ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Optimal Rate ◽  
Stage Iii ◽  
Stage Iii Colon Cancer
Sign in / Sign up

Export Citation Format

Share Document